VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of VolitionRx (NYSE:VNRXGet Free Report) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the stock.

VNRX has been the subject of a number of other reports. Benchmark restated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd. D. Boral Capital reissued a “buy” rating and issued a $5.00 price objective on shares of VolitionRx in a report on Wednesday.

Check Out Our Latest Stock Report on VolitionRx

VolitionRx Price Performance

VNRX stock opened at $0.63 on Friday. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.23. The company has a market cap of $57.92 million, a P/E ratio of -1.74 and a beta of 1.20. The stock’s fifty day moving average price is $0.63 and its 200-day moving average price is $0.66.

Insider Activity at VolitionRx

In other news, Director Guy Archibald Innes acquired 174,764 shares of the firm’s stock in a transaction dated Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the transaction, the director now directly owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Cameron John Reynolds bought 139,811 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were purchased at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the purchase, the chief executive officer now owns 2,117,404 shares in the company, valued at $1,206,920.28. This represents a 7.07 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 358,266 shares of company stock worth $204,212. Corporate insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC increased its holdings in shares of VolitionRx Limited (NYSE:VNRXFree Report) by 78.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent reporting period. 8.09% of the stock is owned by institutional investors and hedge funds.

VolitionRx Company Profile

(Get Free Report)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.

Read More

Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.